Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 11/20 | 0.77 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.77 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.77 |
| ▸ | TSHR | P16473 | 2/20 | 0.77 |
| ▸ | GLA | P06280 | 1/20 | 0.77 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.77 |
| ▸ | APEX1 | P27695 | 1/20 | 0.77 |
| ▸ | NOS1 | P29475 | 10/20 | 0.55 |
| ▸ | NOS3 | P29474 | 6/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | BLM | P54132 | 2/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.52 |
| ▸ | DDAH1 | O94760 | 5/20 | 0.52 |
| ▸ | THPO | P40225 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1738239 | 1.00 | NOS2 (0.77) | NOS2CYP2C19CYP1A2TSHRGLA | |
| Arginine SCHEMBL30577923 | 0.87 | NOS2 (1.00) | NOS2CYP2C19CYP1A2TSHRGLA | |
| Arginine SCHEMBL288835 | 0.87 | NOS2 (1.00) | NOS2CYP2C19CYP1A2TSHRGLA | |
| Arginine SCHEMBL30631154 | 0.87 | NOS2 (1.00) | NOS2CYP2C19CYP1A2TSHRGLA | |
| Arginine SCHEMBL30679324 | 0.87 | NOS2 (1.00) | NOS2CYP2C19CYP1A2TSHRGLA | |
| Arginine SCHEMBL43261 | 0.87 | NOS2 (1.00) | NOS2CYP2C19CYP1A2TSHRGLA | |
| Arginine SCHEMBL288993 | 0.87 | NOS2 (1.00) | NOS2CYP2C19CYP1A2TSHRGLA | |
| Arginine SCHEMBL31547986 | 0.85 | NOS2 (0.96) | NOS2CYP2C19CYP1A2TSHRGLA | |
| SCHEMBL21802133 | 0.85 | NOS2 (0.89) | NOS2CYP2C19CYP1A2TSHRGLA | |
| Arginine SCHEMBL29361849 | 0.85 | NOS2 (0.96) | NOS2CYP2C19CYP1A2TSHRGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240317803-A1 | BCL9 PEPTIDES AND VARIANTS THEREOF | WNTRX PHARMACEUTICALS INC. | 2024-09-26 | — | — | US | disclosed |
| EP-4351656-A1 | PEPTIDES COMPRISING N-FORMYL-HALOGENATED METHIONINE RESIDUES AND ENGINEERED ANTIBODY-PEPTIDE CONJUGATES THEREOF | Eli Lilly and Company (US) | 2024-04-17 | — | — | EP | disclosed |
| CN-117750981-A | Peptides comprising N-formyl-halomethionine residues and engineered antibody-peptide conjugates thereof | 伊莱利利公司 | 2024-03-22 | — | — | CN | disclosed |
| US-11872262-B2 | Means and methods for treating bacterial infections | VIB VZW (BE) | 2024-01-16 | — | — | US | disclosed |
| US-11872262-B2 | Means and methods for treating bacterial infections | VIB VZW (BE) | 2024-01-16 | — | — | US | disclosed |
| US-11591365-B2 | BCL9 peptides and variants thereof | WNTRX PHARMACEUTICALS INC. (US) | 2023-02-28 | — | — | US | disclosed |
| WO-2022261124-A1 | PEPTIDES COMPRISING N-FORMYL-HALOGENATED METHIONINE RESIDUES AND ENGINEERED ANTIBODY-PEPTIDE CONJUGATES THEREOF | ELI LILLY AND COMPANY (US) | 2022-12-15 | — | — | WO | disclosed |
| US-20210077563-A1 | Means and Methods for Treating Bacterial Infections | VIB VZW (BE) | 2021-03-18 | — | — | US | disclosed |
| CN-111836632-A | BCL9 peptides and variants thereof | 温特瑞克斯制药有限公司 | 2020-10-27 | — | — | CN | disclosed |
| EP-3706771-A1 | BCL9 PEPTIDES AND VARIANTS THEREOF | WNTRX Pharmaceuticals Inc. (US) | 2020-09-16 | — | — | EP | disclosed |
| US-20200262867-A1 | BCL9 PEPTIDES AND VARIANTS THEREOF | WNTRX PHARMACEUTICALS INC. | 2020-08-20 | — | — | US | disclosed |
| CN-103038195-B | Device and method for solubilizing, separating, removing and reacting carboxylic acids in oils, fats, aqueous or organic solutions by micro-or nanoemulsification | ULRICH DIETZ (DE) | 2016-04-13 | — | — | CN | disclosed |
| CN-103038195-A | Device and method for solubilizing, separating, removing and reacting carboxylic acids in oils, fats, aqueous or organic solutions by micro-or nanoemulsification | DIETZ ULRICH | 2013-04-10 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240317803-A1 | BCL9 PEPTIDES AND VARIANTS THEREOF | BCL9, BCL9L, BCL3 | NOS2 3517/4885CYP2C19 4413/4885CYP1A2 4758/4885 |
| US-20210077563-A1 | Means and Methods for Treating Bacterial Infections | VIP, MMP8, SLC11A2 | NOS2 209/4885CYP2C19 4484/4885CYP1A2 4842/4885 |
| US-11872262-B2 | Means and methods for treating bacterial infections | VIP, MMP8, SLC11A2 | NOS2 209/4885CYP2C19 4484/4885CYP1A2 4842/4885 |
| US-11591365-B2 | BCL9 peptides and variants thereof | BCL9, BCL9L, BCL3 | NOS2 3517/4885CYP2C19 4413/4885CYP1A2 4758/4885 |
| US-20200262867-A1 | BCL9 PEPTIDES AND VARIANTS THEREOF | BCL9, BCL9L, BCL3 | NOS2 3517/4885CYP2C19 4413/4885CYP1A2 4758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.